Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.55 - $16.11
Previous CloseN/A
Volume43.26K
Average Volume (3M)198.32K
Market Cap
$238.64M
Enterprise Value$109.71M
Total Cash (Recent Filing)$67.23M
Total Debt (Recent Filing)$820.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 07, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding45,283,676
10 Day Avg. Volume176,388
30 Day Avg. Volume198,319
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-11.21
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$13.86Price Target Upside172.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Y-Mabs Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressManagement disclosed results from Part A of the ongoing Phase 1/2 trial, demonstrating tumor uptake of 177 in all nine patients with positive GD2 expression.
Therapy EnhancementThe improved compound will be incorporated into a Bridge study, indicating ongoing efforts to enhance the therapy.
Bears Say
Investor ConfidenceThe timeline for bridging study and additional dose escalation pushes key derisking back, impacting investor confidence.
Therapeutic Index ChallengesThe results for GD2-SADA show that further optimization is required, as no cohort demonstrated an optimal therapeutic index.
Ownership Overview
17.07% Insiders
7.81% Mutual Funds
36.10% Other Institutional Investors
29.94% Public Companies and Individual Investors
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $3.55 and its highest was $16.11 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $238.64M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 58 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on May 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.212 by $0.092.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 45,283,676 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.212. Following the earnings report the stock price went up 2.211%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
Y-Mabs Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.86 (172.83% Upside)
$13.86 (172.83% Upside)
Blogger Sentiment
Bullish
YMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 12.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $76.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.18%
12-Months-Change
Fundamentals
Return on Equity
-29.93%
Trailing 12-Months
Asset Growth
-8.68%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
YMAB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments such as revenue growth in DANYELZA, especially internationally, and advancements in the Radiopharmaceutical segment. However, there were notable challenges like the significant decline in U.S. revenues and reduced R&D expenses. The sentiment is mixed with balanced highlights and lowlights.Read More>YMAB Stock 12 Month Forecast
Average Price Target
$13.86
▲(172.83%Upside)